Deepika Jalota - Mar 3, 2025 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
Chief Development Officer
Signature
/s/ Robert Ticktin, by power of attorney
Stock symbol
PMVP
Transactions as of
Mar 3, 2025
Transactions value $
$0
Form type
4
Date filed
3/5/2025, 06:32 PM
Previous filing
Sep 12, 2024
Next filing
Jul 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMVP Common Stock 123K Mar 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Award $0 +300K $0.00 300K Mar 3, 2025 Common Stock 300K $1.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,741 shares acquired under the Issuer's Employee Stock Purchase Plan as follows: 2,276 shares acquired on May 20, 2021; 359 shares acquired on November 19, 2021; 993 shares acquired on May 20, 2022 and 1,113 shares acquired on November 21, 2022.
F2 Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025.